In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
|Videos|November 29, 2014
Pharmacy Times Asks a Burmans Pharmacist: How Do You Build Patient Trust?
For Vince Canzanese, RPh, director of compounding for Burmans Pharmacy, building patient trust relies on a key factor: not allowing a mailman to become the pharmacist.
Advertisement
For Vince Canzanese, RPh, director of compounding for
“Primarily, we build trust with the patients because we’re a community-based organization,” he says. “We’re here, it’s brick-and-mortar, someone can come in and see me, they know who they’re talking to. It’s not just a voice on the phone.”
Advertisement
Related to this article
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Advertisement
Advertisement